ClinicalTrials.gg
CompletedNCT05093777PIHMultiUpdated May 7, 2026

Program Intensive Habilitation (PIH) for Young Children With Early Brain Damage

An interventional study of Program Intensified Habilitation and Habilitation as usual in Brain Injuries, Cerebral Palsy and Motor Skills Disorders, sponsored by Sorlandet Hospital HF. Completed at 1 site in Norway. Open to participants aged 2 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Sorlandet Hospital HF · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
2 Years to 7 Years
Sex
All
01

Study summary

By longitudinal, prospective research in children with neurodisabilities including severe motor impairments and their parents to explore the beneficial effects of participating in an intensive habilitation program on the child's adaptive functioning and parental empowerment in order to treat and reduce the consequences of early brain damage.

Read the detailed description

Evidence-based knowledge about the effects of intensive training programs for children with severe early brain damage is limited since research on this topic has methodological weaknesses and shows conflicting results. As intensive training programs require extensive efforts from the child, parents and professionals and represent major costs, the importance of scientifically proven effects is considerable. This research project aims to measure the effects of an intensive habilitation program for young children with severe early brain damage on the child's adaptive, motor, language and social functioning and on parental empowerment, family functioning and stress. In this randomized controlled trial (RCT) 90 children will be divided into an intervention group participating in a Norwegian developed program of intensified habilitation of 12 months duration and a control group, who will receive "services as usual" during the same time period. Between-group analyses will then be performed. Due to a stepped wedge design, the control participants will then be offered training in year two of participation. Within-group analysis of results before and after training will then be performed for all participants. Standardized measures with high responsiveness in documenting intervention effectiveness will be used as primary outcome measures. Intensive training groups will be offered in all Health Regions in Norway and if successful be implemented as standard clinical practice.

02

Conditions studied

  • Brain Injuries
  • Cerebral Palsy
  • Motor Skills Disorders
  • Empowerment
  • Parent-Child Relations
  • Parenting

Keywords

  • brain injury
  • cerebral palsy
  • motor disability
  • GMFCS level
  • Pedi-Cat
  • Family Empowerment scale
  • Parenting stress index
03

In context

Brain Injuries

946 studies on the registry are indexed under Brain Injuries; 235 are open to participants now.

This study's enrollment of 93 is above the median of 41 across 612 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Sorlandet Hospital HF is the lead sponsor of 74 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 2 - 6 years at the start of the program
  • a diagnosis of severe cerebral palsy or similar motor disability of non-progressive etiology (GMFCS level IV-V),
  • being able to participate in group sessions
  • having parents who want to take an active part in their child's training
  • least one of the parents must speak fluent Norwegian or English.

Exclusion criteria

Exclusion Criteria:

  • children with progressive disorders
  • co-morbidity like autism spectrum disorder, severe visual and hearing impairments or intractable epilepsy that worsen with physical activity.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Intervention group

    Half of the study participants will be randomized to the intensive habilitation program the first year of program. The second year of program this group of participants will be offered habilitation "as usual".

    Other: Program Intensified Habilitation · Other: Habilitation as usual

  • Other
    Control group

    Half of the study participants will be randomized to "treatment as usual" the first year of program, then offered the intensive program during the second year ("stepped wedge design").

    Other: Program Intensified Habilitation · Other: Habilitation as usual

Interventions

  • OtherProgram Intensified Habilitation

    The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.

    Also known as: PIH Multi

  • OtherHabilitation as usual

    When the participants are not joining the study year containing the intervention program, they will be offered habilitation services "as usual" administered by the primary health care services in the local community.

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Change in Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT)

    Primary evaluation measure for the child

    Time frame: Change from baseline measure at 12 months and after 24 months

  2. Change in Family Empowerment Scale (FES)

    Primary evaluation measure for the parents

    Time frame: Change from baseline measure at12 months and after 24 months

Secondary outcomes

  1. Change in Gross motor function measure (GMFM-88)

    Secondary evaluation measure for the child

    Time frame: Change from baseline measure at 12 months and after 24 months

  2. Change in Parenting Stress Index (PSI)

    Secondary evaluation measure for the parents

    Time frame: Change from baseline measure at 12 months and after 24 months

07

Study locations

1 site
  • Sørlandet Hospital
    Kristiansand, 4626, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Dec 2025, 50 months.

Of 284 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 50 months is above that.

Counting every sponsor, half of 297 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 26, 2021
StartActual
Oct 10, 2021
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05093777
Lead sponsor
Sorlandet Hospital HF
Responsible party
Jon Skranes (Professor dr med, Sorlandet Hospital HF) — Principal investigator
First posted
Oct 26, 2021
Start date
Oct 10, 2021
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
May 7, 2026

Study contacts

Jon Skranes
principal investigator · Sorlandet Hospital HF

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion